 | Up a level |
Jaeger, Ulrich, Tam, Constantine S., Borchmann, Peter, McGuirk, Joseph P., Johansen, Marianne, Waller, Edmund K., Jaglowski, Samantha 
ORCID: 0000-0002-4335-2554, Andreadis, Charalambos, Foley, Stephen R., Westin, Jason R., Fleury, Isabelle, Ho, P. Joy, Mielke, Stephan ORCID: 0000-0002-8325-9215, Teshima, Takanori, Salles, Gilles, Schuster, Stephen J., He, Fiona, Maziarz, Richard T., Mayer, Sebastian, Makita, Shinichi, Kersten, Marie J., Ghosh, Monalisa, Wagner-Johnston, Nina, Kato, Koji, Corradini, Paolo, Goto, Hideki, Colicino, Silvia, Agarwal, Abhijit, Lobetti-Bodoni, Chiara and Bishop, Michael R.
(2022).
Long-term safety for patients with tisagenlecleucel-treated relapsed/refractory diffuse large B-cell lymphoma.
Blood Adv., 6 (16).
S. 4816 - 4821.
AMSTERDAM:
ELSEVIER.
ISSN 2473-9537
Maziarz, Richard T., Waller, Edmund K. ORCID: 0000-0003-0816-6729, Jaeger, Ulrich, Fleury, Isabelle, McGuirk, Joseph, Holte, Harald ORCID: 0000-0001-9799-9428, Jaglowski, Samantha ORCID: 0000-0002-4335-2554, Schuster, Stephen J., Bishop, Michael R., Westin, Jason R., Mielke, Stephan ORCID: 0000-0002-8325-9215, Teshima, Takanori, Bachanova, Veronika, Foley, Stephen R., Borchmann, Peter, Salles, Gilles A., Zhang, Jie, Tiwari, Ranjan, Pacaud, Lida B., Ma, Qiufei and Tam, Constantine S.
(2020).
Patient-reported long-term quality of life after tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma.
Blood Adv., 4 (4).
S. 629 - 638.
WASHINGTON:
AMER SOC HEMATOLOGY.
ISSN 2473-9537
Awasthi, Rakesh, Pacaud, Lida, Waldron, Edward, Tam, Constantine S., Jager, Ulrich, Borchmann, Peter, Jaglowski, Samantha ORCID: 0000-0002-4335-2554, Foley, Stephen Ronan, van Besien, Koen ORCID: 0000-0002-8164-6211, Wagner-Johnston, Nina D., Kersten, Marie Jose, Schuster, Stephen J., Salles, Gilles, Maziarz, Richard T., Anak, Ozlem, del Corral, Christopher, Chu, Jufen, Gershgorin, Irina, Pruteanu-Malinici, Iulian, Chakraborty, Abhijit, Mueller, Karen Thudium and Waller, Edmund K.
(2020).
Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL.
Blood Adv., 4 (3).
S. 560 - 573.
WASHINGTON:
AMER SOC HEMATOLOGY.
ISSN 2473-9537